According to our current and previous findings [12], tumor cells with C190 expression may hinder the efficacy of anti-PD-L1 antibody and T-cell activation through increased sPD-L1, leading to treatment resistance and poor prognosis (Figure 8D). The gene discussed is SPDL1; the disease is neoplasm.